Globus Medical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dan Scavilla
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 11.4% |
| CEO tenure | 2yrs |
| CEO ownership | n/a |
| Management average tenure | 5yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
May 06An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 22% Undervalued
Mar 14Globus Medical Continues To Flex Its Innovation Muscles To Drive Share Growth
Mar 01Globus Medical's (NYSE:GMED) Performance Is Even Better Than Its Earnings Suggest
Feb 24Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture
Feb 08Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jan 21Are Globus Medical, Inc. (NYSE:GMED) Investors Paying Above The Intrinsic Value?
Nov 28Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture
Nov 10At US$76.32, Is Globus Medical, Inc. (NYSE:GMED) Worth Looking At Closely?
Oct 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$123m |
| Sep 30 2023 | n/a | n/a | US$158m |
| Jun 30 2023 | n/a | n/a | US$204m |
| Mar 31 2023 | n/a | n/a | US$201m |
| Dec 31 2022 | US$4m | US$437k | US$190m |
| Sep 30 2022 | n/a | n/a | US$155m |
| Jun 30 2022 | n/a | n/a | US$155m |
| Mar 31 2022 | n/a | n/a | US$142m |
| Dec 31 2021 | US$2m | US$396k | US$149m |
| Sep 30 2021 | n/a | n/a | US$187m |
| Jun 30 2021 | n/a | n/a | US$184m |
| Mar 31 2021 | n/a | n/a | US$122m |
| Dec 31 2020 | US$2m | US$384k | US$102m |
| Sep 30 2020 | n/a | n/a | US$95m |
| Jun 30 2020 | n/a | n/a | US$89m |
| Mar 31 2020 | n/a | n/a | US$148m |
| Dec 31 2019 | US$2m | US$366k | US$155m |
| Sep 30 2019 | n/a | n/a | US$146m |
| Jun 30 2019 | n/a | n/a | US$143m |
| Mar 31 2019 | n/a | n/a | US$150m |
| Dec 31 2018 | US$2m | US$355k | US$156m |
| Sep 30 2018 | n/a | n/a | US$144m |
| Jun 30 2018 | n/a | n/a | US$134m |
| Mar 31 2018 | n/a | n/a | US$118m |
| Dec 31 2017 | US$1m | US$345k | US$107m |
Compensation vs Market: Dan's total compensation ($USD3.82M) is below average for companies of similar size in the US market ($USD8.42M).
Compensation vs Earnings: Dan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Dan Scavilla (58 yo)
2yrs
Tenure
US$3,818,318
Compensation
Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.3yrs | US$2.61m | 16.44% $ 1.1b | |
| President | 2yrs | US$3.82m | no data | |
| CFO & COO | 4.7yrs | US$1.49m | 0% $ 0 | |
| Senior VP | 5.3yrs | US$1.15m | 0% $ 0 | |
| Senior Vice President of Business Development & Investor Relations | no data | no data | no data |
5.0yrs
Average Tenure
56yo
Average Age
Experienced Management: GMED's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.3yrs | US$2.61m | 16.44% $ 1.1b | |
| President | 2yrs | US$3.82m | no data | |
| Independent Director | 12.8yrs | US$391.84k | 0.017% $ 1.2m | |
| Director | less than a year | no data | 0.012% $ 798.9k | |
| Independent Director | 4.9yrs | US$371.84k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$379.34k | 0% $ 0 | |
| Director | less than a year | no data | 0.018% $ 1.2m | |
| Independent Director | 4.3yrs | US$371.84k | 0.0015% $ 102.7k | |
| Independent Director | 21.1yrs | US$369.34k | 0.59% $ 40.6m | |
| Director | less than a year | no data | 0.013% $ 893.2k | |
| Independent Director | 13yrs | US$379.34k | 0.0080% $ 553.9k |
4.9yrs
Average Tenure
61yo
Average Age
Experienced Board: GMED's board of directors are considered experienced (4.9 years average tenure).